Nektar Therapeutics
http://www.nektar.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Nektar Therapeutics
In Swift Challenge To Orange Book Patent Listings, Federal Trade Commission Fills FDA Ministerial Gap
Agency sends letters to 10 companies saying they improperly listed patents in US FDA’s Orange Book covering drug-device combination products. FTC does not specify why it believes the patents were improperly listed.
Roche Makes Play For Bowel Disease Leadership With $7.1bn Roivant Deal
The Swiss pharma company has followed Merck & Co. and Sanofi by buying into the TL1A-inhibitor class, with pharma chief Teresa Graham confident RVT-3101 could be its next best-in-class blockbuster
It’s Official: The Merck-Daiichi Deal Has The Biggest Upfront Ever
But the partners will have to avoid the pitfalls that have bedevilled several other expensive licensing deals.
FDA Change In Bioequivalence Requirements Leads To Downgrade Of Accord’s Generic Tacrolimus
After agency tightened bioequivalence testing recommendations for tacrolimus products post approval, studies found Accord’s generic version of Prograf may deliver higher concentrations, leading agency to downgrade its therapeutic equivalence rating. No problems were found with five other tacrolimus ANDAs.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
-
- Aerogen, Inc.
- Inhale Therapeutic Systems, Inc.
- Inheris Biopharma, Inc.
- Nektar Therapeutics (India) Private Limited
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice